128.10 -3.20 (-2.44%)
Pre-market: 5:34AM EST
|Bid||0.00 x 1300|
|Ask||0.00 x 1000|
|Day's range||126.00 - 133.65|
|52-week range||35.25 - 159.54|
|Beta (5Y monthly)||1.47|
|PE ratio (TTM)||N/A|
|Earnings date||04 May 2021 - 10 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||173.00|
Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following virtual conferences and invited investors to participate by webcast.
According to the U.S. Centers for Disease Control and Prevention (CDC), cancer is the second-leading cause of death in the U.S. (behind heart disease), claiming 599,601 lives in 2019. One area where scientists are making substantial headway is in the field of cancer diagnostics. Two cancer diagnostics-focused stocks worth buying are Exact Sciences (NASDAQ: EXAS) and Guardant Health (NASDAQ: GH).
Shares of Exact Sciences (NASDAQ: EXAS) were sinking 9.2% as of 2:52 p.m. EST on Wednesday. Exact Sciences announced Q4 revenue of $466.3 million, up nearly 58% year over year and above the Wall Street consensus estimate of $446 million. Exact Sciences' research and development expense was much greater than what analysts projected due to the acquisition of Base Genomics.